Published: 2017-03-28

To study the short-term outcome of multimodality treatment on morbidity and quality of life in patients with carcinoma oesophagus

Karamveer Singh, Navneet Jain, Sunil Saini


Background: Oesophageal cancer is sixth most common cause of cancer related deaths worldwide. Despite complete resections, overall survival remained low. To improve the existing treatment combination of chemotherapy and radiotherapy in both neoadjuvant and adjuvant settings was introduced. Impact of treatment on quality of life, morbidities and toxicities associated with multimodality treatment in patients of carcinoma oesophagus was studied prospectively and retrospectively.

Methods: A total of 40 patients histologically proven carcinoma of the oesophagus were enrolled in the study. Study included assessment of clinical features, risk factors, biopsy, multimodality treatment and associated morbidities and toxicities. Quality of Life (QOL) in patients of multimodality treatment assessed using European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 and Core 18 before, immediate post treatment and 6 months after completion of the planned treatment.

Results: In 40 patients, male to female ratio was 1.10:1. Dysphagia was the leading complain. 3 patients were treated using neoadjuvant therapy (chemotherapy and radiotherapy followed by surgery) among them 2 patients expired, 1 patient is under regular follow up. 6 patients underwent upfront surgery followed by adjuvant therapy out of which 3 patients expired,15 patients were treated with curative intent by definitive chemotherapy and radiotherapy out of which only 7 patients survived for >1 year. 16 patients were treated with palliative intent (radiotherapy, chemotherapy, oesophageal stenting and feeding procedures) in which only 1 patient survived for 1 year.

Conclusions: The present study demonstrates that patients over all QOL was reduced after treatment and in the follow up period which was due to the treatment related toxicities but in contrast symptom improvement was observed simultaneously.


Neoadjuvant therapy, Oesophageal cancer, Quality of life

Full Text:



Napier KJ, Scheerer M, Misra S. Esophageal cancer: A Review of epidemiology, pathogenesis, staging workup and treatment modalities. World J Gastrointest Oncol. 2014;6(5):112-20.

Spechler SJ. Barrett esophagus and risk of oesophageal cancer: a clinical review. JAMA. 2013;310:627-36.

Rashid N, Elshaer M. Current management of oesophageal cancer. Br J Med Pract. 2015; 8:17-22.

Socialstyrelsen. Cancer incidence in Sweden 2003. National Board of Health and Welfare. 2003:1-116.

Melhado RE, Alderson D. The Changing face of oesophageal cancer. Cancers. 2010;2:1379-404.

Daly JM, Fry WA, Little AG, Winchester DP, McKee RF, Stewart AK, Fremgen AM. Esophageal cancer: results of an American College of Surgeons Patient Care Evaluation Study. J Am Coll Surg. 2000;190:562-72.

Muwonge R, Ramadas K, Sankila R, Thara S, Thomas G, Vinoda J, et al. Role of tobacco smoking, chewing and alcohol drinking in the risk of oral cancer in Trivandrum, India: a nested case-control design using incident cancer cases. Oral Oncol. 2008;44:446-54.

Talback M, Rosen M, Stenbeck M, Dickman PW. Cancer patient survival in Sweden at the beginning of the third millennium- predictions using period analysis. Cancer Causes Control. 2004;15(9):967-76.

Fitzgerald K, Atie M, Mulsow J, Walsh T. Is lack of public awareness of oesophageal cancer related to its advanced stage at diagnosis? Abstract no 383, 10th World Congress of the ISDE, Adelaide, Australia. 2006;22-5.

Mchembe MD, Endoscopic and clinicopathological patterns of oesophageal cancer in Tanzania: experiences from two tertiary health institutions. World J Surg Oncol. 2013;11:257.

Brown LM, Hoover RN, Greenberg RS, Schoenberg JB, Schwartz AG, Swanson GM, et al. Are racial differences in squamous cell oesophageal cancer explained by alcohol and tobacco use. J Nat Cancer Inst. 1994;86:1340-5.

Keditsu KK, Jiwnani S, Karimundackal G, Pramesh CS. Multimodality management of oesophageal cancer. Indian J Surg Oncol. 2013;4(2):96-104.

Fiorica F, Di Bona D, Schepis F. Preoperative chemoradiotherapy for oesophageal cancer: a systematic review and meta-analysis. Gut. 2004; 53:925-30.

Anbai A, Koga M. Treatment outcomes of chemo-radiotherapy for patients with advanced oesophageal cancer. J Nucl Med Radiat Ther. 2013;4:2-7.

Orditura M, Galizia G. Preoperative treatment of locally advanced oesophageal carcinoma (Review), Int J Oncol. 2013;43:1745-53.

Burmeister BH. Role of radiotherapy in the pre-operative management of carcinoma of the oesophagus. World J Gastrointest Oncol. 2015;7(1):1-5.

Jabbour SK, Thomas CR. Radiation therapy in the postoperative management of oesophageal cancer. J Gastrointest Oncol. 2010;1:102-11.

Villaflor VM, Allaix ME. Multidisciplinary approach for patients with oesophageal Cancer. World J Gastroenterol. 2012;18(46):6737-46.

Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55(2):74-108.

Siersema PD. New developments in palliative therapy. Best Pract Res Clin Gastroenterol. 2006;20(5):959-78.

Jiang XJ, Song MQ, Xin YN, Gao YQ, Niu ZY, Tian ZB. Endoscopic stenting and concurrent chemoradiotherapy for advanced oesophageal cancer: A case-control study. World J Gastroenterol. 2012;18(12):1404-9.

Fietkau R. Definitive and neoadjuvant radiochemotherapy of squamous cell carcinoma of the oesophagus. Onkologie. 2004;27:39-44.

Staal EFWC, Aleman BMP, Boot H. Systematic review of the benefits and risks of neoadjuvant chemoradiation for oesophageal cancer. Br J Surg. 2010;97:1482-96.

Blazeby JM. A prospective longitudinal study examining the quality of life of patients with oesophageal carcinoma. Br J Surg. 1999;86:419-23.

Malmström M. Quality of life measurements as an indicator for timing of support after oesophagectomy for cancer: a prospective study. BMC Health Serv Res. 2015;15:96-103.

Shen H, Wang J. Assessment of health-related quality of life of patients with oesophageal SCC following oesophagectomy using EORTC quality of life questionnaires. Mol Clin Oncol. 2015;3:133-8.